Objectives: Thyroid hormone suppression therapy has been widely used in the treatment of thyroid cancer, but concerns have been raised about the cardiovascular risks of this treatment. The objective of this study was to evaluate long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer (DTC) and to assess the effect of TSH suppression and radioiodine (RAI) treatment on the cardiovascular outcome.
small papillary thyroid cancers, which have an excellent prognosis.
2,3
The increased use of neck area imaging may reveal incidental thyroid cancers with no effect on survival. 4, 5 Despite the increased incidence, mortality from thyroid cancer has remained stable.
2
Diagnosis of small low-risk tumours may expose the patients to aggressive cancer treatment, which may have unfavourable long-term effects. 3 Thyroid hormone suppression therapy (THST) by levothyroxine has been traditionally used as a treatment of thyroid cancer to improve the outcome, but recently the necessity and safety of this treatment in low-risk patients have been questioned. 6, 7 There are concerns about the long-term cardiovascular effects of THST-induced iatrogenic thyrotoxicosis, 6, 7 as the risks of endogenous hyperthyroidism are well known. 8 Increased cardiovascular mortality and an increased risk of atrial fibrillation (AF) have been reported among DTC patients. [9] [10] [11] [12] An association between a low TSH level and an increased risk of cardiovascular mortality has been found in patients treated for DTC. 9 THST has been reported to increase myocardial strain, left ventricular mass and diastolic dysfunction, to impair arterial elasticity and to induce prothrombotic changes in DTC patients. [13] [14] [15] [16] The most recent guidelines on DTC recommend weighing the potential benefits of THST against the possible harms of stringent TSH suppression. [17] [18] [19] For the time being, the appropriate degree of TSH suppression remains unsettled, and there are discrepancies between different guidelines.
17-19
The aim of this study was to evaluate the long-term cardiovascular morbidity and mortality in DTC patients. The secondary aim was to assess the effect of the TSH suppression level and radioiodine (RAI) treatment on the cardiovascular outcome of the patients.
| MATERIALS AND METHODS
In this retrospective study, all the patients treated for DTC between 1981 and 2002 at 2 Finnish University Hospitals (Tampere and Oulu University Hospital, responsible for the specialized health care of 16%
of the Finnish population) were included. Details of this cohort have been recently described in a study analysing the risk of second cancer after the treatment of DTC. 20 In short, this study included 920 consecutive patients, most of whom had a total thyroidectomy (78%) and were subsequently treated with RAI (81% 
| Statistical analysis
The statistical analyses were performed with the IBM spss Statistics of CVD-associated hospital visits, overall mortality and cardiovascular mortality were compared between the patients and the controls using Kaplan-Meier curves and the log-rank test.
The data on all the TSH measurements performed during the study period were available on the patients treated at Tampere University Hospital. The association between the TSH level and the CVD outcome was analysed using a geometric mean 9 of all available TSH measurements after the diagnosis of DTC. The geometric mean TSH level was categorized into 3 groups, according to the American Thyroid Association recommendation (below 0.1, 0.1-0.5, and above 0.5 mU/L). TSH values below the detection limit were given the numeric value of the detection limit of the TSH method (eg, <0.01 mU/L was assumed as 0.01 mU/L). The doses of RAI treatments were obtained from the medical records of both hospitals.
Three different kinds of Cox regression analyses were performed.
The first analysis included all the DTC patients and controls, and the hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for morbidity and mortality due to different CVDs after the diagnosis of DTC. Prevalent CVD was used as a covariate in the analysis to adjust for CVD morbidity before the start of the follow-up.
In the second analysis, hazard ratios for morbidity due to any CVD were determined in the following subgroups of patients and their cor- 
| RESULTS
A total of 901 DTC patients and 4485 controls were included in the study, and 81% of them (n = 733) were female ( Table 1 Table 2 ). The results did not change when the subjects with a prevalent CVD were excluded or when the subdistribution hazards model was used. During the follow-up, 53% (n = 478) of the patients and 48% (n = 2134) of the controls were treated for a CVD.
The mean age during the first treatment due to any CVD was 63.0 (SD Table 2 ). The results did not change when the subjects with prevalent arrhythmias or prevalent AF were excluded, or when the subdistribution hazards model was used.
During the follow-up, 13% of the patients and 11% of the controls were treated for AF. The mean age of the DTC patients during the first treatment for AF was 70.3 (SD 12.0) years and 73.1 (SD 11.2) years for the controls (P = .015). The median time from the beginning of the follow-up to the first treatment due to AF was 13.1 years for the patients and 13.1 (IQR 7.7-18.8) years for the controls (P = .440).
In the subgroup analysis, morbidity due to any CVD was increased in patients under 40 years of age (HR 1.27, 95% CI 1.00-1.60) and also in patients aged 40-59 years (HR 1.23, 95% CI There was no difference in the overall mortality (HR 0.98, 95%
CI 0.85-1.12) between the DTC patients and the controls ( Table S3 ). The result remained unchanged when the subdistribution hazards model was used.
Atrial fibrillation was recorded as an underlying cause, a contributory cause or the direct cause of death in 5% (n = 13) of the patients and 6% (n = 77) of the controls (P = .535). The most common CVD cause of death was coronary artery disease, which was the underlying cause of death in 17% (n = 42) of the patients and 25% (n = 315) of the controls. Of the DTC patients, 7.7% (n = 69) died of the thyroid cancer.
Among the deceased DTC patients, 28% (n = 69) died of the thyroid cancer, 32% (n = 81) of a CVD and 40% (n = 100) from other causes.
In the control group, 43% (n = 533) died of a CVD, and 57% (n = 704) from other causes.
Altogether, 11 292 TSH measurements from 469 patients were available for the analyses. Of the TSH measurements, 5068 (45%)
were below the detection limit. The median number of TSH measurements per patient during the follow-up was 23 (interquartile range
[IQR] 14-33).
The patients in the different TSH groups differed regarding the age at DTC diagnosis (P < .001). The median age of patients with a Of the DTC cohort, 81% (n = 732) were treated with RAI ablation.
The median cumulative dose of RAI was 100 mCi (IQR 100-150 mCi).
In the subgroup analysis, the patients treated with RAI ablation had an increased risk of CVD morbidity (HR 1.18, 95% CI 1.05-1.31) compared to the corresponding controls, contrary to the patients not treated with RAI vs their respective controls (HR 1.07, 95% CI 0.85-
1.34) (Figure 4, panels C-D).
In the Cox regression analysis including only the patients, age (HR predicted morbidity due to any CVD, whereas the TSH level or the cumulative dose of RAI did not have a statistically significant effect on CVD morbidity.
| DISCUSSION
To our knowledge, this is the largest study evaluating cardiovascular morbidity and mortality among DTC patients with a long follow-up time. This study is also the first one to report the risk of other cardiovascular diseases in addition to AF in DTC. We found that the risk of hospital treatment due to any cardiovascular disease is increased among patients treated for DTC, compared with age-and gendermatched control group. The increased risk is mostly accountable to an increased risk of AF.
Based on previous studies, the survival rate of patients diagnosed with a DTC is excellent. 3 No difference in the all-cause mortality was found between the patients with DTC, and the matched control group in the present study, either. Given the similar life expectancy compared with the general population, the co-morbidities, the quality of life and the burden of the cancer treatments should be taken into account, in addition to the risk of cancer recurrence. Studies on endogenous subclinical and clinical hyperthyroidism indicate an increased risk of cardiovascular morbidity and mortality. 8, 21, 22 Findings from endogenous thyroid disease, however, cannot be generalized on thyroid F I G U R E 3 All-cause mortality and cardiovascular mortality in the patients treated for differentiated thyroid cancer, compared with the matched control group (log-rank test)
cancer patients, because endogenous and exogenous thyrotoxicosis are not entirely comparable conditions, and they may impose different risks on the cardiovascular system.
11,23
Previous studies on DTC patients have reported an increased incidence of AF, but no association between the TSH level and AF incidence, although such an association is known to exist in endogenous hyperthyroidism. 24 properties.
13
In contrast to our results indicating decreased cardiovascular mor- that the number of nonthyroid cancer-related deaths in T1-3M0 DTC patients was lower compared with age-and sex-matched cohort of the general population. In our study, the cardiovascular mortality was lower among the patients than controls. If a DTC patient dies of thyroid cancer, he/she cannot reach the end-point of a cardiovascular or another nonthyroid cancer-related death, which may underestimate the risk of cardiovascular death in the DTC cohort. 26 In this study, cardiovascular mortality remained lower among the patients than among the controls, when the competing event of noncardiovascular death was taken into account.
One explanation for the lower cardiovascular mortality among the DTC patients might be the lifelong follow-up of DTC patients, during which cardiovascular risk factors may be revealed and treated earlier, compared with the general population. 26 Hypothyroidism is related to hypercholesterolaemia, atherosclerosis and an increased risk of coronary artery disease. 28 In contrast to hypothyroidism, exogenous subclinical thyrotoxicosis might have beneficial effects, protecting from coronary artery disease.
In our study, the death certificate data from Statistics Finland and the underlying cause of death were used for both the patients F I G U R E 4 Cumulative cardiovascular morbidity by the mean TSH level (panels A-C) and by the cumulative radioiodine dose (panels D-F) in the differentiated thyroid cancer patients compared to the respective control group (log-rank test) and the controls. In Finland, the registration of an underlying cause of death is mandatory. Also, the entry of diagnosis codes to HILMO is mandatory when a patient is discharged from a hospital.
Therefore, the high quality and completeness of the data obtained from these nationwide registers are a significant strength of this study. 29 Previous studies indicate that the validity of CVD diagnoses in these registers is high.
29,30
However, the register-based study method has limitations.
The HILMO register includes only visits in the specialized healthcare system, which may underestimate the incidence of nonsevere cardiovascular diseases among both the patients and the controls. A limitation is that we did not have information on cardiovascular risk factors, such as smoking, diabetes or body mass index. Also, we did not have information on the prevalence of endogenous thyroid disorders among the controls, nor did we have information on the use of levothyroxine or antithyroid drugs. Both hyperthyroidism and hypothyroidism have been found to increase cardiovascular morbidity.
Regardless of the possibility of thyroid disorders among the control group, the risk of cardiovascular morbidity was increased among the DTC patients.
Because of the retrospective study method, conclusions cannot be drawn about the causality between DTC treatment and CVD morbidity, that is, whether the increased cardiovascular morbidity is due to the cancer or its treatment, or a shared risk factor for DTC and cardiovascular morbidity.
In conclusion, we found that the survival rate of patients diagnosed with a DTC is excellent, but the risk of cardiovascular diseases is increased among patients treated for DTC, compared with age-and gender-matched controls. The increased risk is mostly accountable to an increased risk of AF. The patients with a low mean TSH level (<0.1 mU/L) have an increased risk of CVD. While the study rises concerns about the long-term cardiovascular effects of THST-induced iatrogenic thyrotoxicosis, the optimal level of TSH remains to be settled in future studies.
